Lilly agrees to acquire Calytrix Bio for $1.5bn

​

Eli Lilly and Company has agreed to acquire Calytrix Bio in a deal valued at up to $1.5bn to advance an investigational biparatopic antibody targeting mCALR-driven ET and MF.

The post Lilly agrees to acquire Calytrix Bio for $1.5bn appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.